Latest Stock Market News

In September last year, such advances had contracted 2.9%, central bank data on sectoral deployment of bank credit showed. On a year-on-year (y-o-y) basis, non-food bank credit increased 17% in September 2022, compared with 6.8% a year ago.

Banks are relative stragglers in the race for deposits. Average rates being offered in specific segments by some lenders are sometimes less than sovereign bond yields.

Bain Capital held a 4.24% stake in Axis Bank through its three funds - BC Asia Investments VII, BC Asia Investments III, and Integral Investments South Asia IV - as on September 30

Bain Capital held a 4.24% stake in Axis Bank through its three funds - BC Asia Investments VII, BC Asia Investments III, and Integral Investments South Asia IV - as on September 30

The company in the filing said the split is being considered to enhance the liquidity in the capital market, to widen shareholder base and to make the shares more affordable to small investors

Consumer price growth in the 19 countries sharing the euro accelerated to 10.7% in October from 9.9% a month earlier

Choksi, who was the chairman and managing director as well as part of promoter group of Gitanjali Gems, is the maternal uncle of Nirav Modi. Both of whom are facing charges of defrauding state-owned Punjab National Bank (PNB) of more than Rs 14,000 crore.

Sebi, last month, had disposed of the adjudication proceedings against four individuals, including Vora, in the case pertaining to alleged circulation of unpublished price-sensitive information (UPSI) about the financial results of half a dozen companies, including TCS and UltraTech Cement.

The capping of ISINs is expected to reduce fragmentation in the primary market and enhance liquidity in the secondary market.Of the 14 ISINs, a maximum of nine ISINs maturing per financial year will be allowed for plain vanilla debt securities. Within this limit of nine ISINs, the issuer can issue both secured and unsecured debt securities.

The operational performance, however, will be hit by higher research and development costs, input prices, and continued erosion in prices in the US generics market. Sun Pharma’s US-based subsidiary Taro Pharmaceutical Industries, which released Q2 earnings last week, reported an operating loss of $6.8 million against a profit of $24.4 million a year ago, primarily due to pricing pressure in the generics drug market.